Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Non-Current Deffered Revenue (2016 - 2025)

Vistagen Therapeutics' Non-Current Deffered Revenue history spans 9 years, with the latest figure at $176000.0 for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 61.23% year-over-year to $176000.0; the TTM value through Dec 2025 reached $176000.0, down 61.23%, while the annual FY2025 figure was $391000.0, 85.38% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $176000.0 at Vistagen Therapeutics, down from $336000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $2.7 million in Q1 2024 and bottomed at $176000.0 in Q4 2025.
  • The 4-year median for Non-Current Deffered Revenue is $454000.0 (2024), against an average of $994280.0.
  • The largest annual shift saw Non-Current Deffered Revenue crashed 91.1% in 2021 before it tumbled 49.18% in 2024.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $276500.0 in 2021, then soared by 586.94% to $1.9 million in 2023, then crashed by 76.1% to $454000.0 in 2024, then tumbled by 61.23% to $176000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Non-Current Deffered Revenue are $176000.0 (Q4 2025), $336000.0 (Q3 2025), and $221000.0 (Q2 2025).